Dr. Teresa Lynn Helsten, MD

Dr. Helsten practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Helsten's NPI, 1265408678, was assigned on February 24, 2006. Dr. Helsten graduated from UC Davis School of Medicine in 1998. Dr. Helsten holds California license A71996.

Dr. Helsten's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Helsten's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Helsten is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Helsten to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Helsten practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Helsten's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Helsten is board certified in hematology by the American Board of Internal Medicine. Dr. Helsten is licensed in California.

Dmand AI lists breast cancer and lung cancer among the conditions Dr. Helsten treats.

CMS data shows 493 Medicare services from Dr. Helsten across 3 procedure codes in 2024, for 146 Medicare patients. Medicare paid $31,260 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 146 Medicare patients who saw Dr. Helsten in 2024. The largest group is 65 to 74, with 73 patients. 75% of them have cancer, and 66% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Helsten's median patient age at 63, with 92% women.

In 2024, Dr. Helsten wrote 665 Medicare Part D claims for 101 patients. 68% of them were for generic drugs. CMS names the drug for 520 of them, across 17 drugs with 11 or more claims each, at $2,053,809 in total drug cost. In 2023, CMS named 516 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Helsten for performance year 2024, reported as part of a group. Dr. Helsten accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Helsten as offering telehealth.

Dmand AI links 28 papers to Dr. Helsten, published from 2005 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Biomarkers, Tumor. Dr. Helsten has published most often in J Adolesc Young Adult Oncol. Dr. Helsten's most frequent co-authors are Richard Bruce Schwab, MD, Barbara A. Parker, MD and Judy C. Boughey, MD.

Dmand AI links Dr. Helsten to 6 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Acrocephalosyndactylia. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Helsten that name 1 trial.

CMS Open Payments shows 5 general payments to Dr. Helsten from 3 drug and device companies from 2016 to 2021. Education make up the largest share, 65% of the total. Pfizer Inc. paid the most, $27. It also lists 1 research payment totaling $7,076 in 2018, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Helsten, most recently CMS Stage 1 EHR in 2013.

Dr. Helsten graduated from UC Davis School of Medicine in 1998.

Dr. Helsten is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.